Anti-amyloid drugs

Anti-amyloid drugs, also known as anti-amyloid antibodies (AAA), are a class of monoclonal antibodies developed to treat Alzheimer's disease. The first drug in the class to be developed, in the early 2000s, was bapineuzumab, but it did not show effectiveness in later-stage trials. The first drug to be FDA approved was aducanumab in 2021.